Anti-Infectives Study Experience

Anti-Infectives Study Experience

PPD ensures rapid study deployment across critical emerging markets for anti-infective and antifungal research. Our operations and regulatory experts are available to provide local knowledge of standards of care and regulations.

  • PPD has managed clinical trials for anti-infectives across Europe, Latin America, the Middle East, North America and Asia. In the past five years, we have conducted more than 50 anti-infective studies.1
  • During that time, PPD has conducted approximately 30 Phase I-IV studies involving various antifungal drug classes, including invasive fungal infections, aspergillosis, candidiasis and cryptococcosis.1

With operations in key markets, we leverage our robust technical infrastructure to minimize the challenges of large-scale global research.

 

 

1. These numbers don't include our work in the government sector, which is tracked separately.

A new white paper explores the nuances of the hepatitis C virus (HCV) that continue to impact the treatment strategies for the disease.
PPD's white paper focuses on new FDA guidances on influenza and CABP.
Adding investigative sites benefits a complicated urinary tract infection study.